Bladder Cancer

Papers
(The median citation count of Bladder Cancer is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives11
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer10
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models9
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort8
Urologists and Advanced Practice Providers Evaluating Hematuria7
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer6
Clinical Trials Corner Issue 9(2)6
Comparison of Robotic vs Open Cystectomy: A Systematic Review5
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter5
Management of bladder cancer in kidney transplant recipients: A narrative review5
Standard vs extended lymphadenectomy for muscle invasive bladder cancer5
Expression of PD-1 and PD-L1 in BCG-treated NMIBC5
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review4
Clinical Trials Corner Issue 10(2)4
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Organoid models in bladder cancer: From bench to bedside?4
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer4
A New Standard of Care for Bladder Cancer4
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes3
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC3
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Challenging Cases in Urothelial Cancer: Case 333
Commentary on Novitas LCD3
Challenging Cases in Urothelial Cancer: Case 263
Y Chromosome Loss and Bladder Cancer3
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma2
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors2
Open vs Robotic Surgery2
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy2
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?2
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer2
Clinical Trials Corner Issue 7(4)2
Challenging Cases in Urothelial Cancer: Case 272
Clinical Trials Corner Issue 8(2)2
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer2
Implementing a New Standard of Care1
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis1
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics1
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates1
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review1
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile1
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol1
Clinical Trials Corner Issue 9(4)1
Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively1
When a ‘routine’ TURBT is not routine: Lessons from SEER-medicare1
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study1
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells1
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors1
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease1
Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette–Guérin therapy in patients with non-muscle invasive bladder cancer1
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer1
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG1
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy1
BCG in Immunocompromised Patients: Is it effective? Is it safe?1
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma1
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States1
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis1
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer1
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E1
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer 0
A New Functional Gene, Zinc Finger Protein 485 (ZNF485), is Involved in Bladder Cancer Proliferation0
The Development of a Video-based Nutrition Education Curriculum for Patients Undergoing Radical Cystectomy0
Clinical Trials Corner Issue 10(1)0
Clinical trials corner issue 11(1)0
What is a Bladder Cancer Molecular Subtype?0
Combination of Two T1 Substaging Systems (T1a/b/c and T1m/e) Better Predicts Tumor Outcomes in Patients with T1 High Grade Bladder Cancer0
Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer0
Bladder cancer journal as official IBCN partner; strengthening global collaboration in bladder cancer0
Clinical Trials Corner Issue 8(4)0
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer0
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy0
LncRNA HEIH/miR-4500/IGF2BP1/c-Myc Feedback Loop Accelerates Bladder Cancer Cell Growth and Stemness0
Challenging Cases in Urothelial Cancer: Case 240
The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study10
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer0
Optimal Perioperative Chemotherapy for Muscle Invasive Bladder Cancer0
A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma0
Clinical Trials Corner Issue 9(1)0
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors0
Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer0
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer0
Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications0
Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome0
The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands0
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer0
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?0
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study0
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer0
A Procedural Checklist for Transurethral Resection of Bladder Tumors (TURBT) Enhances Operative Dictation and Assesses Surgeon Accuracy of Tumor Characteristic Predictions0
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer0
Repeat TURBT in large volume high-grade non-invasive bladder cancer0
Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life0
Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies0
Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial0
The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence0
Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis0
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management0
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer0
Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma0
The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis0
Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank0
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility0
Challenging Cases in Urothelial Cancer: Case 250
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays0
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety0
Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study0
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward0
The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC)0
Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration0
Challenging Cases in Urothelial Cancer: Case 320
Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study0
Challenging Cases in Urothelial Cancer: Case 220
Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model0
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis0
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 290
North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence0
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer0
Impact of lymphovascular invasion and histological variants on BCG-treated high-grade NMIBC prognosis0
What is a Bladder Cancer Molecular Subtype? – Counterpoint0
Effect of Bacille Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer After Prostate Radiotherapy0
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer0
Salvage for BCG Unresponsive and Recurrent Disease0
0.076775074005127